La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RegenETP Gestione

Gestione criteri di controllo 2/4

RegenETP's Il CEO è Richard Hague, nominato in Apr2020, ha un mandato di 4.33 anni. possiede direttamente 0.62% delle azioni della società, per un valore di $ 488.98. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.2 anni e 7.2 anni.

Informazioni chiave

Richard Hague

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4.5yrs
Proprietà del CEO	0.6%
Durata media del management	5.4yrs
Durata media del Consiglio di amministrazione	7.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

May 10

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Feb 19

PolarityTE to raise up to $10M with at-the-market offering

Jan 12

PolarityTE under pressure on pricing $8M registered direct offering

Dec 22

PolarityTE perks up after securing first U.S. patent

Nov 30

PolarityTE EPS beats by $0.02, beats on revenue

Nov 09

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Richard Hague rispetto agli utili di RegenETP?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$480k	US$449k	-US$8m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$1m	US$359k	-US$30m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$38m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$996k	US$358k	-US$43m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$2m	US$273k	-US$92m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Richard sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Richard con le performance aziendali.

AMMINISTRATORE DELEGATO

Richard Hague (64 yo)

4.5yrs

Mandato

US$479,808

Compensazione

Mr. Richard Hague is Director of Remedium Bio, Inc since 2022. He serves as President at PolarityTE, Inc. since August 2019 and its Chief Executive Officer since August 2021 and also served as its Chief Op...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Hague	President	4.5yrs	US$479.81k	0.62% $ 4.4k
Nikolai Sopko	Chief Scientific Officer and VP of R&D	6.3yrs	Nessun dato	Nessun dato
Rich Haerle	Vice President of Investor Relations & Strategy	6.4yrs	Nessun dato	Nessun dato
Mark Lehman	Chief Legal Officer	no data	Nessun dato	Nessun dato
Angela Ziegler	Vice President of Marketing & Public Relations	no data	Nessun dato	Nessun dato
Alain Adam	Vice President of Sales	6.3yrs	Nessun dato	Nessun dato
Jon Anthony Burrows	Senior VP of Corporate Development & President of Contract Services	no data	Nessun dato	Nessun dato
Ryan Mathis	Chief Medical Officer	3.1yrs	Nessun dato	Nessun dato
Kolby Day	Senior Vice President of Manufacturing Operations	1.9yrs	Nessun dato	Nessun dato

5.4yrs

Durata media

Gestione esperta: Il team dirigenziale di RGTP.Q è esperto e expertise (durata media dell'incarico 5.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Hague	President	1.2yrs	US$479.81k	0.62% $ 4.4k
Michael Callahan	Member of Clinical Advisory board	no data	Nessun dato	Nessun dato
Stephen Milner	Member of Clinical Advisory Board	7.8yrs	Nessun dato	Nessun dato
Michael Grant	Member of Clinical Advisory Board	7.8yrs	Nessun dato	Nessun dato
Anand Kumar	Member of Clinical Advisory Board	7.8yrs	Nessun dato	Nessun dato
Anthony Tufaro	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Trinity Bivalacqua	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Shannath Merbs	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Ryan Katz	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Martin Robson	Member of Clinical Advisory Board	7.3yrs	Nessun dato	Nessun dato
William Hickerson	Member of Clinical Advisory Board	7.3yrs	Nessun dato	Nessun dato
Jeffrey Shupp	Member of Clinical Advisory Board	7.3yrs	Nessun dato	Nessun dato

7.3yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RGTP.Q sono considerati esperti (durata media dell'incarico 7.2 anni).

RegenETP Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Independent Chairman of the Board recently bought US$259k worth of stock

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

New major risk - Share price stability

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$1.25

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Consensus revenue estimates fall by 40%

Price target decreased to US$15.38

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PolarityTE down 10% on lower-than-expected Q2 revenue

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

Price target decreased to US$15.38

First quarter 2022 earnings: Revenues miss analyst expectations

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$1.08

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

Consensus forecasts updated

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

PolarityTE Is Not A DeFi Coin

Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?

Independent Chairman of the Board recently bought US$259k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Analysts update estimates

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: US$1.54

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

PolarityTE to raise up to $10M with at-the-market offering

New 90-day high: US$1.32

PolarityTE under pressure on pricing $8M registered direct offering

New 90-day low: US$0.63

PolarityTE perks up after securing first U.S. patent

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.18 loss per share

New 90-day low: US$0.81